Completed NA INTERVENTIONAL 2-arm NCT05054114

Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19

Sponsor: SPP Pharmaclon Ltd.

Conditions Acute Respiratory Disease COVID-19 Respiratory Infection

Interventions Interferon gamma human recombinant (IFN-G)

Updated 4 times since 2021 Last updated: Mar 4, 2024 Started: Dec 21, 2020 Primary completion: May 25, 2021 Completion: Sep 2, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05054114, this NA trial focuses on Acute Respiratory Disease and COVID-19 Respiratory Infection and remains completed. Sponsored by SPP Pharmaclon Ltd., it has been updated 4 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Oct 2021 — Jul 2024 [monthly]

Completed NA

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SPP Pharmaclon Ltd.

Data source: SPP Pharmaclon Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia